EBS Long Call Strategy
EBS (Emergent BioSolutions Inc.), in the Healthcare sector, (Drug Manufacturers - Specialty & Generic industry), listed on NYSE.
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services.
EBS (Emergent BioSolutions Inc.) trades in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a market capitalization of approximately $429.8M, a beta of 2.33 versus the broader market, a 52-week range of 5.31-14.06, average daily share volume of 883K, a public-listing history dating back to 2006, approximately 900 full-time employees. These structural characteristics shape how EBS stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 2.33 indicates EBS has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a long call on EBS?
A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.
Current EBS snapshot
As of May 15, 2026, spot at $7.98, ATM IV 68.80%, IV rank 4.87%, expected move 19.72%. The long call on EBS below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this long call structure on EBS specifically: EBS IV at 68.80% is on the cheap side of its 1-year range, which favors premium-buying structures like a EBS long call, with a market-implied 1-standard-deviation move of approximately 19.72% (roughly $1.57 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated EBS expiries trade a higher absolute premium for lower per-day decay. Position sizing on EBS should anchor to the underlying notional of $7.98 per share and to the trader's directional view on EBS stock.
EBS long call setup
The EBS long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With EBS near $7.98, the first option leg uses a $8.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed EBS chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 EBS shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $8.00 | $0.88 |
EBS long call risk and reward
- Net Premium / Debit
- -$87.50
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$87.50
- Breakeven(s)
- $8.88
- Risk / Reward Ratio
- Unbounded
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.
EBS long call payoff curve
Modeled P&L at expiration across a range of underlying prices for the long call on EBS. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -99.9% | -$87.50 |
| $1.77 | -77.8% | -$87.50 |
| $3.54 | -55.7% | -$87.50 |
| $5.30 | -33.6% | -$87.50 |
| $7.06 | -11.5% | -$87.50 |
| $8.83 | +10.6% | -$4.84 |
| $10.59 | +32.7% | +$171.49 |
| $12.35 | +54.8% | +$347.82 |
| $14.12 | +76.9% | +$524.15 |
| $15.88 | +99.0% | +$700.48 |
When traders use long call on EBS
Long calls on EBS express a bullish thesis with defined risk; traders use them ahead of EBS catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
EBS thesis for this long call
The market-implied 1-standard-deviation range for EBS extends from approximately $6.41 on the downside to $9.55 on the upside. A EBS long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current EBS IV rank near 4.87% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on EBS at 68.80%. As a Healthcare name, EBS options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to EBS-specific events.
EBS long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. EBS positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move EBS alongside the broader basket even when EBS-specific fundamentals are unchanged. Long-premium structures like a long call on EBS are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current EBS chain quotes before placing a trade.
Frequently asked questions
- What is a long call on EBS?
- A long call on EBS is the long call strategy applied to EBS (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With EBS stock trading near $7.98, the strikes shown on this page are snapped to the nearest listed EBS chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are EBS long call max profit and max loss calculated?
- Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the EBS long call priced from the end-of-day chain at a 30-day expiry (ATM IV 68.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$87.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a EBS long call?
- The breakeven for the EBS long call priced on this page is roughly $8.88 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current EBS market-implied 1-standard-deviation expected move is approximately 19.72%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long call on EBS?
- Long calls on EBS express a bullish thesis with defined risk; traders use them ahead of EBS catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
- How does current EBS implied volatility affect this long call?
- EBS ATM IV is at 68.80% with IV rank near 4.87%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.